- Home
- DARE vs WYY Comparison
DARE vs WYY Comparison
Compare DARE & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- WYY
- Stock Information
- Founded
- DARE N/A
- WYY 1991
- Country
- DARE United States
- WYY United States
- Employees
- DARE N/A
- WYY N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- WYY EDP Services
- Sector
- DARE Health Care
- WYY Technology
- Exchange
- DARE Nasdaq
- WYY Nasdaq
- Market Cap
- DARE 31.9M
- WYY 32.7M
- IPO Year
- DARE N/A
- WYY 1998
- Fundamental
- Price
- DARE $3.21
- WYY $3.71
- Analyst Decision
- DARE Strong Buy
- WYY Strong Buy
- Analyst Count
- DARE 4
- WYY 1
- Target Price
- DARE $20.33
- WYY $7.00
- AVG Volume (30 Days)
- DARE 64.6K
- WYY 92.5K
- Earning Date
- DARE 11-14-2024
- WYY 11-13-2024
- Dividend Yield
- DARE N/A
- WYY N/A
- EPS Growth
- DARE N/A
- WYY N/A
- EPS
- DARE N/A
- WYY N/A
- Revenue
- DARE $1,881,316.00
- WYY $133,124,648.00
- Revenue This Year
- DARE $388.48
- WYY $25.94
- Revenue Next Year
- DARE $67.37
- WYY $13.22
- P/E Ratio
- DARE N/A
- WYY N/A
- Revenue Growth
- DARE 88.13
- WYY 31.67
- 52 Week Low
- DARE $3.05
- WYY $1.65
- 52 Week High
- DARE $7.56
- WYY $4.52
- Technical
- Relative Strength Index (RSI)
- DARE 36.32
- WYY 49.04
- Support Level
- DARE $3.42
- WYY $3.65
- Resistance Level
- DARE $4.60
- WYY $4.19
- Average True Range (ATR)
- DARE 0.32
- WYY 0.18
- MACD
- DARE -0.09
- WYY 0.00
- Stochastic Oscillator
- DARE 2.11
- WYY 33.33
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically the company generates a majority of its revenue from the United States and rest from Europe.